Compare HGBL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGBL | ESLA |
|---|---|---|
| Founded | 1937 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 45.6M |
| IPO Year | 1998 | N/A |
| Metric | HGBL | ESLA |
|---|---|---|
| Price | $1.24 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.85 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 92.0K | 43.0K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $20,129,000.00 | N/A |
| Revenue This Year | $11.92 | N/A |
| Revenue Next Year | $13.52 | N/A |
| P/E Ratio | $61.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $0.78 |
| 52 Week High | $2.32 | $3.15 |
| Indicator | HGBL | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 41.07 |
| Support Level | $1.20 | $0.97 |
| Resistance Level | $1.45 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 25.06 | 39.29 |
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It operates in four segments. The Auction and Liquidation segment, which operates as a full-service auction, appraisal, and asset advisory firm, includes the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment. The Refurbishment & Resale segment acquires, refurbishes, and supplies specialized laboratory equipment. Brokerage segment, through NLEX, brokers charged-off receivables in the U.S. and Canada on behalf of financial institutions. The Specialty Lending segment, which provides specialty financing solutions to investors in charged-off and nonperforming asset portfolios.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.